Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • ‘Confidence is a big problem’: China’s economic recovery loses steam
    • Spain’s PM Pedro Sánchez calls snap election after regional defeats
    • Russia pounds Ukraine with missile and drone barrage
    • Erdoğan extends rule into third decade with Turkish election victory
    • Republican leaders try to quell debt deal revolt as US counts down to default
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • India files criminal complaint against Rolls-Royce and BAE
      • Temasek cuts pay of employees behind failed $275mn bet on FTX
      • PwC suspends 9 partners over Australian tax leak scandal
      • Insolvency risk rises for larger UK companies as inflation bites
      • US retailers count the cost of surging shopping crime
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      Most Read
      • Temasek cuts pay of employees behind failed $275mn bet on FTX
      • Commercial property’s big reset will present opportunities
      • Turkey’s lira weakens as economists warn of economic challenge
      • Turkish lira hits new low after Erdoğan’s election victory
      • Bank turmoil does not justify mission creep by deposit insurance
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
      Most Read
      • How to buy a global $20bn company for nothing
      • De-risking trade with China is a risky business
      • Commercial property’s big reset will present opportunities
      • The UK needs a new deal for its highly taxed graduates
      • Now the UK is finally tackling ‘Londongrad’, it’s time the US upped its game
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      Most Read
      • ‘Everyone has the right to completely log off’: what bosses think about the right to disconnect
      • Wellcome Leap’s Regina Dugan: ‘Odds are irrelevant, if what you’re trying to do is important’
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • The UK’s best bakeries: the readers’ picks
      • The treasures of Mallorca’s Tramuntana mountains
      • The best summer road cycling gear
      • Succession finale review — one last twist of the knife
      • GCHQ’s Jeremy Fleming: ‘Xi doesn’t want to see Putin humiliated’
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    Novo Nordisk AS

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Thursday, 18 May, 2023
      LexDrugs research
      Weight-loss drugs: long-term risks could blunt investors’ appetite for remedies Premium content

      Manufacturers racing to build what could be one of industry’s biggest markets must tread with care

    • Thursday, 16 March, 2023
      Novo Nordisk suspended from UK industry group after rule violation

      Regulators find Danish drugmaker sponsored ‘disguised’ promotional campaign

    • Sunday, 12 February, 2023
      Novo Nordisk apologises for not disclosing sponsorship of anti-obesity training

      Healthcare professionals encouraged to prescribe group’s weight loss drug as part of ‘disguised’ promotional campaign

    • Wednesday, 28 December, 2022
      News in-depthDrugs research
      Race is on to develop new generation of weight-loss drugs

      Eli Lilly, Amgen, Pfizer and Regeneron follow Novo Nordisk into obesity treatments worth billions

    • Friday, 23 December, 2022
      LexDrugs research
      Medicines: triumph of science in 2022 is worth celebrating Premium content

      From obesity drugs to cancer treatments, this year should be remembered for pharmaceutical advances

    • Monday, 21 November, 2022
      News in-depthHealthcare
      Big Pharma targets $50bn obesity drugs market as demand booms

      Eli Lilly seeks approval for weight loss medication as Novo Nordisk battles supply crunch for Wegovy

    • Thursday, 14 July, 2022
      FT Magazine
      A new ‘miracle’ weight-loss drug really works — raising huge questions

      Novo Nordisk’s Wegovy uses a hormone to regulate hunger. It’s wildly effective, but is it misguided?

    • Thursday, 18 June, 2020
      Intellectual property
      University spinouts seek fair reward for vital R&D work

      Academic institutions must balance private and public interests

    • Monday, 7 October, 2019
      FT News Briefing podcast9 min listen
      HSBC cuts, Biden fights back, trade ructions

      HSBC embarks on a cost-cutting drive that threatens up to 10,000 jobs

    • Tuesday, 1 October, 2019
      FT SeriesThe Company of the Future: Profit and Purpose
      Insulin maker Novo Nordisk walks moral tightrope

      Danish pharma group has faced criticism in the US over its pricing

    • Wednesday, 25 September, 2019
      FTfmCorporate governance
      Loyalty shares can promote better long-term stewardship 

      Dual-class structures carry risks but can also give patient investors a stronger voice

    • Thursday, 10 January, 2019
      Drug prices
      Sanofi and Novo Nordisk press ahead with US insulin prices rises

      Cost increase for essential medicine comes as drugmakers face political pressure

    • Tuesday, 23 October, 2018
      Lex
      Obesity drugs: fat chance Premium content

      Better marketing might be the answer to thin sales

    • Tuesday, 18 September, 2018
      European companies
      Novo Nordisk sheds 400 staff as it refocuses R&D efforts

      Danish pharma group seeks to exploit potential of AI and big data

    • Friday, 17 August, 2018
      European companies
      Novo Nordisk buys UK university biotech spin-out Ziylo

      Deal could eventually be worth more than $800m if milestones are met

    • Wednesday, 8 August, 2018
      European companies
      Shares in Novo Nordisk fall after warning on US price cuts

      Pricing pressures prompt cautious outlook at Danish pharma group

    • Wednesday, 9 May, 2018
      News in-depthIran nuclear deal
      China poised to profit as Europe companies feel Iran pain

      EU companies may feel brunt of US sanctions after Trump pulls out of nuclear deal

    • Wednesday, 2 May, 2018
      European companies
      Novo Nordisk shares climb as it lifts sales and profit

      Danish drugmaker beats expectations with 6% increase in operating earnings

    • Wednesday, 28 February, 2018
      Pharmaceuticals sector
      Novo to invest $165m in first ‘superbug’ venture fund

      Repair Impact Fund will help start-ups develop treatment aimed at drug-resistant bacteria

    • Thursday, 1 February, 2018
      European companies
      Drugmakers highlight US pricing pressure in results

      Novo Nordisk misses revenue expectations while Roche cautions on stagnant sales

    • Thursday, 1 February, 2018
      European companies
      Danish drug maker Novo Nordisk’s profit edges higher as chair departs
    • Monday, 29 January, 2018
      LexEuropean companies
      Sanofi/Novo Nordisk: blood money Premium content

      If the Danish group wants to bulk up its sickly biopharma unit, it will need to be less cautious

    • Monday, 29 January, 2018
      Pharmaceuticals sector
      Sanofi beats Novo Nordisk with €3.9bn Ablynx deal

      Biotech blockbuster acquisition is second in a week and latest in sector M&A boom

    • Monday, 29 January, 2018
      European companies
      Sanofi agrees €3.9bn deal for Belgian biotech Ablynx

      French group beats interest from Novo Nordisk to make second major acquisition in a week

    • Monday, 8 January, 2018
      European companies
      Novo Nordisk makes €2.6bn approach for Belgium’s Ablynx

      Shares in target company jump after it rejects unsolicited bid as undervalued

    Previous page You are on page 1 Next page

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsFT Schools

    Tools

    PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition

    Top sections

    • Home
    • World
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
      • Australia & NZ
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
    • Markets
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports

    FT recommends

    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Live Events
    • FT Forums
    • Board Director Programme
    • myFT
    • Portfolio
    • Today's Newspaper (ePaper)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In